Depomed reiterated its opposition to the Horizon Pharma acquisition, reminding its shareholders in a letter that the company believes it is being undervalued and that the Nucynta franchise holds greater value than the deal.
Days after Horizon commenced its tender offer for the outstanding shares of Depomed -- taking its hostile offer straight to...






